Curis to Present Updated Data from the TakeAim Leukemia Study prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
LEXINGTON, Mass., April 5, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April.
Curis, Inc : Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule.